-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US2075231017 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 103M |
|---|---|
| PE Ratio | None |
| Beta | -0.27 |
| Target Price | 6.5 |
| Dividend Yield | None |
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CNTB using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025